ArticleDiscover oncology2025
Expression and functional diversity of the glucagon-like peptide-1 receptor across tumor types.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer.Internal and emergency medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeGlucagon-like peptide-1 receptor (GLP-1R) agonists are widely used to treat type 2 diabetes mellitus (T2DM) and obesity. Emerging evidence suggests potential links between GLP-1R signaling and cancer risk or progression, but its role in tumor biology remains unclear. This study investigated GLP-1R expression and prognostic value across multiple cancer types using large-scale genomic datasets.
methodsWe analyzed GLP-1R mRNA expression using data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and the Human Protein Atlas. Expression patterns in tumors were compared to normal tissues, including samples from rapid autopsies. Survival analyses were conducted across cancer types, and GLP-1R gene alterations were assessed via cBioPortal.
resultsGLP-1R expression showed marked variation across cancers. It was lower in breast, lung, and colon cancers, but elevated in esophageal, kidney, and thyroid tumors compared to normal tissues. Higher GLP-1R expression correlated with improved overall survival in low-grade glioma but with worse outcomes in lung squamous cell carcinoma. Patterns of disease-free survival varied similarly. Genetic alterations in GLP-1R were rare, with amplifications most common, particularly in esophageal and ovarian cancers.
conclusionGLP-1R shows tissue-specific expression and prognostic relevance across cancer types. The low expression of GLP-1R across cancer types and the low frequency of genetic alterations suggest a limited direct role of GLP-1R mutations in cancer progression, but its variable expression may influence tumor behavior. Further research is needed to clarify both the functional role of GLP-1R in cancer biology and the safety and therapeutic potential of GLP-1R agonists in oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.